Artia Global Partners portfolio
Concentrated managerInvestment firmPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Artia Global Partners reported a $526M portfolio of 47 positions to the SEC as of the end of Q2 2026. Its largest positions are ABVX, INSM, TRVI. During the quarter it opened Alkermes plc. and Guardant Health and exited Eli Lilly.
Sections with a free account
What changed this quarter
24 positions with a change (6 new, 10 added to, 3 trimmed, 5 sold); also, 2 exited through an acquisition or merger. 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Eli Lilly−6.7 ppof portfolioSold out7.9% → —
- BrightSpring Health Services+862%more sharesIncreased0.5% → 6.9%
- Alkermes plc.+4.5 ppof portfolioNew— → 4.5%
- Travere Therapeutics+380%more sharesIncreased0.5% → 3.7%
- Revolution Medicines+48%more sharesIncreased2.7% → 6.6%
- Abivax−14%fewer sharesReduced15.1% → 13.1%
- Guardant Health+1.1 ppof portfolioNew— → 1.1%
- Absci+1.0 ppof portfolioNew— → 1.0%
- Quest Diagnostics+60%more sharesIncreased1.8% → 2.6%
- Cytokinetics+334%more sharesIncreased0.2% → 1.1%
- Celcuity+281%more sharesIncreased0.4% → 1.2%
- Insmed−6.3%fewer sharesReduced23.2% → 11.9%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- AbivaxABVX13.1%
- InsmedINSM11.9%
- Trevi TherapeuticsTRVI7.8%
- BrightSpring Health ServicesBTSG6.9%
- Revolution MedicinesRVMD6.6%
- ArgenxARGX5.2%
- Alkermes plc.ALKS4.5%
- Travere TherapeuticsTVTX3.7%
- AstrazenecaAZN3.5%
- NewAmsterdam PharmaNAMS3.2%
- Dianthus TherapeuticsDNTH3.0%
- Quest DiagnosticsDGX2.6%
- Ionis PharmaceuticalsIONS2.2%
- EyePointEYPT2.1%
- AlumisALMS1.5%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 100%
How its portfolio changed (8 quarters)
Q2 2026: 47
Q2 2026: 66%
Q2 2026: 16.9%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
13F filings with amendments or confidential positions
- 13F Q3 2025 ↗filed Nov 14, 2025Amendment of Nov 14, 2025 (replaces the original) ↗
Declared options (1)
Besides stocks, Artia Global Partners declared 1 put (they gain if the stock falls) with a notional of $15.8M. The 13F reports the value of the underlying shares, not the premium paid, so these figures look large and are not added to the portfolio. Nor does it say whether the option is bought or written, or its strike or expiry: it may be a hedge.
- PUTState Street SPDR S&P Biotech ETFXBInew this quarter$15.8M
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Investment firm, per its Form ADV of Mar 31, 2026 (high confidence).
The data, as reported: ARTIA GLOBAL PARTNERS LP (CRD 322091): 7.B private funds: 1 hedge (gross assets $779M); 5.D assets by client type: pooled vehicles 100% (of $779M)
The type comes from a rule applied to that data. If it looks wrong, tell us.
Similar managers by type and size
Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.
- Unio CapitalInvestment firm · $526M
- DAFNA Capital ManagementInvestment firm · $524M
- Webs Creek Capital ManagementInvestment firm · $528M
- Stieven Capital AdvisorsInvestment firm · $524M
- Manitou Investment ManagementInvestment firm · $532M
- Palo Duro Investment PartnersInvestment firm · $518M